Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-03-22
2011-03-22
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S653000, C558S169000
Reexamination Certificate
active
07910626
ABSTRACT:
The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
REFERENCES:
patent: 6004565 (1999-12-01), Chiba et al.
patent: 2002/0037895 (2002-03-01), Baenteli et al.
patent: 0 627 406 (1994-12-01), None
patent: 1 002 792 (2000-05-01), None
patent: 1 201 236 (2002-05-01), None
patent: 02/18395 (2002-03-01), None
patent: 03/020313 (2002-03-01), None
patent: 02/064616 (2002-08-01), None
patent: 02/076995 (2002-10-01), None
Mazurais et al., “Cell Type-Specific Localization of Human Cardiac SIP Receptors,” J. Histochem. Cytochem., vol. 50, No. 5, p. 661-669 (2002).
Hwang et al., “FTY720, a New Immunosuppressant, Promotes Long-Term Graft Survival and Inhibits the Progression of Graft Coronary Artery Disease in a Murine Model of Cardiac Transplantation,” Circulation, vol. 100, No. 12, pp. 1322-1329 (1999); CAPLUS 1999:658439.
Miyamato et al., Therapeutic Effects of FTY720, a New Immnunosuppressive Agent, in a Murine Model of Acute Viral Myocarditis, Journal of the American College of Cardiology, vol. 37, No. 6, pp. 1713-171 8, (2001); CAPLUS 2001 :382829.
Anandasabapathy et al., Innovative drug treatments for viral and autoimmune myocarditis., 1998, Journal of Clinical Pharmacology, vol. 38, No. 4, (Abstract Only).
Cleland et al., “What is the Optimal Medical Management of Ischaemic Heart Failure?”, British Medical Bulletin, vol. 59, pp. 135-148, (2001).
Karliner, “Lysophospholipids and the Cardiovascular System,” Biochimica et Biophysica Acta, vol. 1582, No. 1-3, pp. 216-221, (2002).
Lllliom et al., Sphingosylphosphocholine is a Naturally Occurring Lipid Mediator in Blood Plasma: A Possible Role in Regulating Cardiac Function via Sphingolipid Receptors, Biochemical Journal, vol. 355, No. 1, pp. 189-197, (2001).
Lynch, “Lysophospholipid Receptor Nomenclature,” Biochimica et Biophysica Acta, vol. 1582, No. 1-3, pp. 70-71, (2002).
Pyne et al., “Spingosine 1-phosphate Signaling via the Endothelial Differentiation Gene Family of G-Protein-Coupled Receptors,” Pharmacology and Therapeutics, vol. 88, pp. 115-131, (2000).
Mandala, S., et al:. “Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists”, Science, vol. 296, pp. 346-349, Apr. 12, 2002.
Schmouder et al., “FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects”, J Clin Pharmacol, vol. 46, pp. 895-904, (2006).
Brinkmann Volker
Feutren Gilles
Hof Robert Paul
Anderson James D
Chapman Jennifer
DeBenedictis Karen
Finn Meghan
McAvoy Cozette M.
LandOfFree
Use of S1P receptor agonists in heart diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of S1P receptor agonists in heart diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of S1P receptor agonists in heart diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690318